Sunitinib Alternatives Compared
| Sunitinib | Sutent (sunitinib) | Votrient (pazopanib) |
|
|---|
| Sunitinib | Sutent (sunitinib) | Votrient (pazopanib) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Renal Cell Carcinoma, Gastrointestinal Stromal Tumor, Pancreatic Cancer. Sunitinib may also be used for purposes not listed in this medication guide. |
Prescription only
Sutent is an oral capsule that may be taken once daily to treat certain types of RCC and other advanced cancers. It may be taken every day or for 4 weeks on, 2 weeks off schedule. It has been... View more |
Prescription only
Prescribed for Soft Tissue Sarcoma, Renal Cell Carcinoma. Votrient may also be used for purposes not listed in this medication guide. |
||||||||||||||||||||||||
| More about Sunitinib | More about Sutent (sunitinib) | More about Votrient (pazopanib) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Sunitinib has an average rating of 7.2 out of 10 from a total of 35 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 23% reported a negative effect. |
Sutent has an average rating of 7.5 out of 10 from a total of 30 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 19% reported a negative effect. |
Votrient has an average rating of 8.2 out of 10 from a total of 82 ratings on Drugs.com. 77% of reviewers reported a positive effect, while 7% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Sunitinib prices |
View all Sutent prices |
View all Votrient prices |
||||||||||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Sutent |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
60 hours |
60 hours |
30.9 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 459 drugs are known to interact with Sunitinib:
|
A total of 459 drugs are known to interact with Sutent:
|
A total of 678 drugs are known to interact with Votrient:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
January 26, 2006 |
January 26, 2006 |
October 19, 2009 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.